Cardiff Oncology (CRDF) Metrics: History & Chart

Cardiff Oncology, Inc.(CRDF)

Biotechnology · San Diego, CA

$1.08-0.06 (-5.26%)

Delayed quote: Oct 6, 2026, 12:19 PM EDT

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

San Diego, CA

31 employees

www.cardiffoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mani Mohindru

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-5.00%
30D Total Return	+4.59%
YTD Total Return	-59.43%
1Y Total Return	-47.95%
3Y Total Return	-5.80%
5Y Total Return	-83.62%
10Y Total Return	-99.65%
15Y Total Return	-99.55%
20Y Total Return	-99.67%

2026	-59.43%
2025	-35.25%
2024	+193.24%
2023	+5.71%
2022	-76.71%
2021	-66.59%
2020

CAGR TTM	-47.78%
CAGR 3Y	-1.97%
CAGR 5Y	-30.36%
CAGR 10Y	-43.20%
CAGR 15Y	-30.20%
CAGR 20Y	-24.80%

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

CRDF Valuation Metrics

CRDF Stock Price Metrics

CRDF Dividend Metrics

CRDF Growth Rate Metrics

CRDF Discounted Cash Flow Metrics

CRDF Returns By Period

CRDF Yearly Returns

CRDF Average Annual Returns By Period (CAGR)

CRDF Revenue Metrics

CRDF PE Ratio Metrics

CRDF PS Ratio Metrics

CRDF PB Ratio Metrics

CRDF Price to Free Cash Flow Ratio Metrics

CRDF Debt to Equity Ratio Metrics

CRDF PEG Ratio Metrics

CRDF FCF Yield

CRDF Earnings Yield

CRDF EBITDA Yield

CRDF OCF Yield

CRDF EV/EBIT Ratio Metrics

CRDF EV/EBITDA Ratio Metrics

CRDF EV/Assets Ratio Metrics

CRDF EV/Sales Ratio Metrics

CRDF Current Ratio Metrics

CRDF Quick Ratio Metrics

CRDF ROIC Metrics

CRDF Return on Assets Metrics

CRDF Return on Equity Metrics

CRDF Net Profit Margin Metrics

CRDF Gross Profit Margin Metrics

CRDF Tax Rate Metrics

PS Ratio	153.49
PS Ratio Avg TTM	220.70
PS Ratio Avg 3Y	219.61
Current VS TTM Avg	-30.45%
Current VS 3Y Avg	-30.11%
Current VS 5Y Avg	-29.48%

PB Ratio	2.94
PB Ratio Avg TTM	2.71
PB Ratio Avg 3Y	2.34
Current VS TTM Avg	+8.36%
Current VS 3Y Avg	+25.88%
Current VS 5Y Avg	+66.34%

PFCF Ratio	16.04
PFCF Ratio Avg TTM	17.74
PFCF Ratio Avg 3Y	15.91
Current VS TTM Avg	-9.57%
Current VS 3Y Avg	+0.81%
Current VS 5Y Avg	-8.39%

Debt/Equity Ratio	0.02
Debt/Equity Ratio Avg TTM	0.02
Debt/Equity Ratio Avg 3Y	0.02
Current VS TTM Avg	-9.43%
Current VS 3Y Avg	-30.70%
Current VS 5Y Avg	-30.53%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	6.24%
FCF Yield Avg TTM	5.92%
FCF Yield Avg 3Y	6.70%
Current VS TTM Avg	+5.38%
Current VS 3Y Avg	-6.85%
Current VS 5Y Avg	-0.74%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	1.85
Ev/Assets Ratio Avg TTM	1.79
Ev/Assets Ratio Avg 3Y	1.62
Current VS TTM Avg	+3.08%
Current VS 3Y Avg	+14.49%
Current VS 5Y Avg	+47.27%

Ev/Sales Ratio	136.28
Ev/Sales Ratio Avg TTM	202.08
Ev/Sales Ratio Avg 3Y	192.46
Current VS TTM Avg	-32.56%
Current VS 3Y Avg	-29.19%
Current VS 5Y Avg	-26.94%

Current Ratio	3.30
Current Ratio Avg TTM	3.77
Current Ratio Avg 3Y	5.74
Current VS TTM Avg	-12.61%
Current VS 3Y Avg	-42.60%
Current VS 5Y Avg	-67.19%

Quick Ratio	3.30
Quick Ratio Avg TTM	3.77
Quick Ratio Avg 3Y	5.74
Current VS TTM Avg	-12.61%
Current VS 3Y Avg	-42.60%
Current VS 5Y Avg	-67.19%

ROIC	(159.30%)
ROIC Avg 3Y	(88.52%)
ROIC Avg 5Y	(65.55%)
Current VS 3Y Avg	-79.97%
Current VS 5Y Avg	-143.02%
Current VS 10Y Avg	-65.26%

ROA	(107.29%)
ROA Avg TTM	(19.51%)
ROA Avg 3Y	(16.12%)
Current VS TTM Avg	-449.88%
Current VS 3Y Avg	-565.42%
Current VS 5Y Avg	-746.01%

ROE	(150.95%)
ROE Avg TTM	(114.27%)
ROE Avg 3Y	(83.36%)
Current VS TTM Avg	-32.10%
Current VS 3Y Avg	-81.07%
Current VS 5Y Avg	-142.22%

Net Profit Margin	(7884.06%)
Net Profit Margin Avg TTM	(12572.21%)
Net Profit Margin Avg 3Y	(7948.90%)
Current VS TTM Avg	+37.29%
Current VS 3Y Avg	+0.82%
Current VS 5Y Avg	+10.57%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	(1814.05%)
Gross Pft Margin Avg 3Y	76.72%
Current VS TTM Avg	+105.51%
Current VS 3Y Avg	+30.34%
Current VS 5Y Avg	+15.58%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	-100.00%